AZD 1080, a novel GSK 3 inhibitor, rescues synaptic plasticity deficits in rodent brain and exhibits peripheral target engagement in humans
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Abnormal tau phosphorylation resulting in detachment of tau from microtubules and aggregation are critical events in neuronal dysfunction, degeneration, and neurofibrillary pathology seen in Alzheimer's disease. Glycogen synthase kinase‐3β (GSK 3β) is a key target for drug discovery in the treatment of Alzheimer's disease and related tauopathies because of its potential to abnormally phosphorylate proteins and contribute to synaptic degeneration. We report the discovery of AZD 1080, a potent and selective GSK 3 inhibitor that demonstrates peripheral target engagement in Phase 1 clinical studies. AZD 1080 inhibits tau phosphorylation in cells expressing human tau and in intact rat brain. Interestingly, subchronic but not acute administration with AZD 1080 reverses MK‐801‐induced deficits, measured by long‐term potentiation in hippocampal slices and in a cognitive test in mice, suggesting that reversal of synaptic plasticity deficits in dysfunctional systems requires longer term modifications of proteins downstream of GSK 3β signaling. The inhibitory pattern on tau phosphorylation reveals a prolonged pharmacodynamic effect predicting less frequent dosing in humans. Consistent with the preclinical data, in multiple ascending dose studies in healthy volunteers, a prolonged suppression of glycogen synthase activity was observed in blood mononuclear cells providing evidence of peripheral target engagement with a selective GSK 3 inhibitor in humans.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Querfurth, H. W., & LaFerla, F. M. (2010) · New England Journal of Medicine · doi:10.1056/nejmra0909142 · Cited by 4,569
Synaptic Plasticity: Multiple Forms, Functions, and Mechanisms
Citri, A., & Malenka, R. C. (2008) · Neuropsychopharmacology · doi:10.1038/sj.npp.1301559 · Cited by 2,323
Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders
Ballatore, C., Lee, V. M.-Y., & Trojanowski, J. Q. (2007) · Nature Reviews Neuroscience · doi:10.1038/nrn2194 · Cited by 2,174 · cited 2×
“The importance of AZD1080 as a specific GSK3 inhibitor was validated by its capacity to interfere with tau hyperphosphorylation, a pathological event believed to play an important role in AD (Ballatore et al. 2007).”
BackgroundThe GSK3 hypothesis of Alzheimer’s disease
Hooper, C., Killick, R., & Lovestone, S. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05194.x · Cited by 1,191 · cited 1×
“In addition, GSK3b has been implicated to have a role in synaptic plasticity in neuronal networks because of its influence on diverse substrates involved in signaling pathways (Hooper et al. 2008; Peineau et al. 2008).”
BackgroundHanger, D. P., Hughes, K., Woodgett, J. R., Brion, J.-P., & Anderton, B. H. (1992) · Neuroscience Letters · doi:10.1016/0304-3940(92)90774-2 · Cited by 737
Pei, J.-J., Braak, E., Braak, H., Grundke-Iqbal, I., Iqbal, K., Winblad, B., & Cowburn, R. F. (1999) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/00005072-199909000-00011 · Cited by 459
Ishiguro, K., Shiratsuchi, A., Sato, S., Omori, A., Arioka, M., Kobayashi, S., Uchida, T., & Imahori, K. (1993) · FEBS Letters · doi:10.1016/0014-5793(93)81066-9 · Cited by 402
Hernández, F., Borrell, J., Guaza, C., Avila, J., & Lucas, J. J. (2002) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2002.01269.x · Cited by 372
Aβ1-42 inhibition of LTP is mediated by a signaling pathway involving caspase-3, Akt1 and GSK-3β
Jo, J., Whitcomb, D. J., Olsen, K. M., Kerrigan, T. L., Lo, S.-C., Bru-Mercier, G., Dickinson, B., Scullion, S., Sheng, M., Collingridge, G., et al. (2011) · Nature Neuroscience · doi:10.1038/nn.2785 · Cited by 305
Cited by
GSK-3 as potential target for therapeutic intervention in cancer
McCubrey, J. A., Steelman, L. S., Bertrand, F. E., Davis, N. M., Sokolosky, M., Abrams, S. L., Montalto, G., D’Assoro, A. B., Libra, M., Nicoletti, F., et al. (2014) · Oncotarget · doi:10.18632/oncotarget.2037 · Cited by 508
Targeting hepatic glucose metabolism in the treatment of type 2 diabetes
Rines, A. K., Sharabi, K., Tavares, C. D. J., & Puigserver, P. (2016) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.151 · Cited by 375
Glycogen synthase kinase-3 inhibitors: Rescuers of cognitive impairments
King, M. K., Pardo, M., Cheng, Y., Downey, K., Jope, R. S., & Beurel, E. (2014) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.07.010 · Cited by 171
“Memory impairment in the contextual fear conditioning task induced by administration to mice of MK-801, an N-methyl-Daspartate receptor antagonist, was reversed by treatment twice daily for 3 days with the GSK3 inhibitor AZD1080 (4 or 15 µmol/kg; oral gavage) (Georgievska et al., 2013).”
MethodRole of GSK-3β Inhibitors: New Promises and Opportunities for Alzheimer’s Disease
Shri, S. R., Manandhar, S., Nayak, Y., & Pai, K. S. R. (2023) · Advanced Pharmaceutical Bulletin · doi:10.34172/apb.2023.071 · Cited by 71
Tau-targeting therapy in Alzheimer’s disease: Critical advances and future opportunities
Guo, Y., Li, S., Zeng, L.-H., & Tan, J. (2022) · Ageing and Neurodegenerative Diseases · doi:10.20517/and.2022.16 · Cited by 61
Metadata
- Authors
- Georgievska, B., Sandin, J., Doherty, J., Mörtberg, A., Neelissen, J., Andersson, A., Gruber, S., Nilsson, Y., Schött, P., Arvidsson, P. I., Hellberg, S., Osswald, G., Berg, S., Fälting, J., & Bhat, R. V.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2013-03-11
- Volume
- 125
- Issue
- 3
- Pages
- 446-456
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W1979694143
- Cited by
- 120
- References
- 9
- FWCI
- 4.49
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: AZD 1080, a novel GSK 3 inhibitor, rescues synaptic plasticity deficits in rodent brain and exhibits peripheral target engagement in humans. https://app.cochat.ai/papers/10.1111/jnc.12203
- The paper
- Georgievska, B., Sandin, J., Doherty, J., Mörtberg, A., Neelissen, J., Andersson, A., Gruber, S., Nilsson, Y., Schött, P., Arvidsson, P. I., Hellberg, S., Osswald, G., Berg, S., Fälting, J., & Bhat, R. V. (2013). AZD 1080, a novel GSK 3 inhibitor, rescues synaptic plasticity deficits in rodent brain and exhibits peripheral target engagement in humans. Journal of Neurochemistry. https://doi.org/10.1111/jnc.12203
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.